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Site of the action of a synthetic atrial natriuretic peptide evaluated in
humans. The renal site of the natriuretic effect of human, atrial
natriuretic peptide (hANP) was studied using clearance techniques in
eight salt—loaded normal volunteers undergoing maximal water diuresis.
Lithium was used as a marker of proximal sodium reabsorption.
According to a two—way, single blind, crossover design, hANP (Met'2-
(3-28)-eicosahexapeptide, (2 /sg/min) or its vehicle (Ve) were infused for
two hours, followed by a two—hour recovery period. Blood pressure,
heart rate and inulin clearance remained unchanged. During hANP
infusion, the filtration fraction increased slightly from 19.6 to 24.3% (P
<0.001), fractional water excretion rose transiently at the beginning of
the infusion. Fractional excretion of sodium increased markedly from
2.2% to 7.4% (P < 0.001) but remained unchanged with Ye. ANP
increased fractional excretion of lithium slightly from 46 to 58% (P <
0.01), while it remained stable at 47% during Ye. The distal tubular
rejection fraction of sodium calculated from sodium and lithium clear-
ances rose markedly from 4.7 to 13% (P < 0.001) and returned to 6.2%
at the end of the recovery period. Thus, under salt loading and water
diuresis conditions, hANP infusion did not alter GFR, but reduced
proximal reabsorption of sodium, and markedly enhanced the fraction
of sodium escaping distal tubular reabsorption, suggesting that hANP-
induced natriuresis is due, for an important part, to inhibition of sodium
reabsorption in the distal nephron.
In animals, atrial natriuretic factor (ANF) has been shown to
increase glomerular filtration rate (GFR) and electrolyte and
water excretion [1-4]. Since an increase in GFR could enhance
sodium excretion, it has been argued that the ANF induced
natriuresis and diuresis is causally related to this increase [5,6].
However, the natriuretic and diuretic effect of ANF has also
been observed even in the absence of any GFR changes [7—14].
The renal mechanism(s) and site(s) of action of the natriuretic
effect of ANF remain therefore controversial.
Our study was designed to assess in normal human volun-
teers the renal site of action of a synthetic atrial natriuretic
polypeptide. To evaluate changes of tubular function on water
and sodium transport, we used clearance techniques, and in
particular lithium clearance as an indicator of the rate of
end—proximal tubular fluid delivery [15,16]. This value, together
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with simultaneous measurement of sodium clearance, allows
the difference between proximal and distal net tubular transport
of sodium to be distinguished.
Methods
Eight male volunteers, aged 24 to 29 years (mean = 26),
weighing between 62 and 81 kg (mean 71) participated in the
study. Each volunteer had a medical history taken and under-
went a complete physical examination. Routine laboratory tests
were done before and after the administration of the drug. The
nature and the purpose of the study had been explained, and a
written informed consent had been previously obtained, The
protocol was approved by the Hospital Ethics Committee.
Design of the study
The subjects were maintained on a normal sodium diet to
which 5 g/day of NaCl were added as salt capsules during the
five days preceding each study day. Urines were collected
during the 24 hours of the fifth day to measure electrolyte
excretion. On the study day, the volunteers came to the hospital
at 7:00 a.m. after an overnight fast. Upon arrival, they were
weighed and made comfortable on a bed. They remained
supine, except for voiding, and fasted throughout the study
procedure. Three intravenous catheters were inserted into
antecubital veins, two in the same forearm for infusion of inulin,
p-amino-hippurate (PAH) and lithium in a glucose/saline solu-
tion and of the experimental drug or its solvent; the third
catheter was inserted into the contralateral forearm for blood
drawing.
One dose of synthetic atrial natriuretic Met'2-(3-28)-eicosa-
hexapeptide (hANP) or its vehicle alone (mannitol 5%, 8 mllhr)
were infused and compared at a one week interval according to
a single blind, randomized, two—way crossover protocol. Each
study phase consisted of a one hour baseline, a two hour
treatment and a two—hour recovery period.
Between 7:00 and 8:30 a.m., the volunteers drank 20 mi/kg
body weight of water. From 8:30 to the end of the study, the
volunteers were given an isotonic solution ( glucose 5% and ¼
saline 0.9%) in water intravenously at a rate of 0.2 mI/mm .kg
body weight. After a priming dose, i.v. infusion of inulin, PAH
and lithium in 0.9% saline was started (2.0 ml/min); the concen-
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trations were calculated to provide plasma concentrations of
approximately 400 g/ml, 20 ig!ml and 0.1 mmol/liter, respec-
tively. Urinary clearances of inulin (glomerular filtration rate:
GFR), PAH (effective renal plasma—flow: ERPF), and lithium
were measured. After a 1.5 hour equilibration period and two
30-minute baseline measurements (control periods), an infusion
was started at a flow rate of 8 mllhr, to deliver either the vehicle
(5% mannitol) or hANP (2 igImin).
Blood pressure and heart rate were measured at 30 minute
intervals at the midtime of each clearance period. Blood sam-
ples for the measurement of electrolytes, osmolality, inulin and
PAH and hematocrit were drawn at half—hourly intervals.
Blood samples for the measurement of arginine—vasopressin
were drawn before and at 1, 2, 3 and 4 hours after starting the
hANP infusion. Urines were collected at 30-minute intervals by
spontaneous voiding.
Drugs and chemicals
hANP (L-364,670) is a polypeptide of 26 aminoacids synthet-
ized by Merck, Sharp and Dohme Research Laboratories,
Rahway, New Jersey, USA [17]. The sequence corresponds to
a-human atrial natriuretic peptidc 18,19] except for the dele-
tion of the two aminoterminal aminoacids serine and leucine.
Inulin (Inulin Purissimum) was purchased from Laevosan—
Gesellschaft, (Linz Donau, Austria) and PAH (Nephrotest,
sodium salt of p-aminohippuric acid) from Biologische Ar-
beitsgemeinschaft GmBH (Lich, Hessen, Germany). A concen-
trated sterile lithium chloride water solution was prepared by
the Hospital pharmacy, and appropriately diluted in 0.9%
saline.
Analytical methods
The method used to determine arginine vasopressin has been
previously reported [20]. Inulin and PAH concentrations in
plasma and urine were measured by a microadaptation on a
Technicon Autoanalyser (Tarrytown, New York, USA) of a
diphenylamine procedure [21] and by an adaptation of a Brat-
ton—Marshall procedure [221 on an Uvikon 860 spectrophotom-
eter (Kontron Instruments, Zurich, Switzerland), respectively.
Osmolality was determined as freezing point depression with a
Roebling Automatik Mikroosmometer (Berlin, Germany). So-
dium and potassium were analyzed by direct flame photometry
(Instrumentation Laboratory, Watertown, Massachusetts
USA). Lithium was measured in duplicate in plasma and urine
by flame emission photometry (Zeiss, Oberkochen, West Ger-
many). A standard curve was determined for each set of
samples. In order to minimize any possible interference from
urinary electrolytes, concentrations of Na and K were first
measured in urine samples, and the working Li standard solu-
tions were adjusted thereafter so as to range within 15% of Na
and K concentrations present in the diluted urine samples.
Calcium, phosphate, urate and plasma chloride were quanti-
fied photometrically (Greiner Electronics Selective Analyzer
0300, Langenthal, Switzerland). Magnesium was determined
by atomic absorption spectrophotometry (Varian International,
model AA-1275, Zug, Switzerland) and urinary chloride with a
Corning chloride meter. A hand—held digital pH-meter in auto-
matic temperature compensation mode (Model 105, Coming,
Halstead, Essex, England) was used for the determination of
urinary pH.
Constant infusions were carried out with syringe pumps
Pei-fusor ED 1-300 (B. Braun, Melsungen, Germany) for hANP
and volumetric infusion and transfusion pumps Doltron PIM
717 (Uster, Switzerland) for inulin, PAH, lithium and glucose!
saline.
Renal parameters and statistical evaluation
Clearances (C) were calculated by the traditional method
using the formula C = U, x V!P, where U, and P,, represent
urine and plasma concentrations of x, and V the urinary flow
rate in milliliters per minute. Fractional excretion (FEz) was
calculated as the clearance of x divided by the clearance of
inulin (C!GFR). Plasma concentrations used for clearance
determinations were calculated by averaging initial and final
values of each clearance period. The filtration fraction (FF) was
calculated as the ratio of inulin over PAH clearances
(GFRIERPF). Free water clearance (CH2O) was calculated as
urinary flow rate (V) minus osmolar clearance (Cosm). Delivery
of chloride to the distal tubules (DDc1) and distal fractional
chloride absorption (DFAc1) were calculated as [(CH20 +
Cc1)!GFR x 100] and [CH20!CH,o + Cci)], respectively [23].
Fractional sodium reabsorption in the proximal and in the
postproximal tubule was estimated as 1-FEL, and ((FELr
FENa)!FELI) x 100, respectively. Absolute distal reabsorption
of sodium was calculated as the difference between the clear-
ances of lithium and sodium time the plasma concentration of
sodium. The absolute rate of proximal reabsorption of isotonic
fluid corresponds to the difference between the clearance of
inulin and that of lithium.
Numerical results are expressed as mean 1 SEM. The
statistical significance of differences was evaluated by a two
way analysis of variance with or without replication followed by
the Fisher, least significant—difference test, with P < 0.05 as the
minimum level of significance [24]. Regression analysis was
performed using the least squares method and the slopes of the
regression lines were compared using a common slope regres-
sion test based on Student's t-test [24].
Results
Blood pressure and heart rate
No statistically significant change was observed in blood
pressure, although a slight trend toward a decrease in blood
pressure was noted at the end of the hANP infusion and during
most of the recovery period. No effect on heart rate was evident
as the result of hANP infusion.
Renal hemodynamics
Mean GFR remained constant at 122 4.6 and 120 3,7
ml/min (control periods), 117 2.9 and 125 3.0 (treatment
periods), 118 2.2 and 116 2.7 ml!min (recovery periods)
during the vehicle and the hANP infusion phases, respectively
(Table 1).
ERPF was stable during the vehicle infusion at a mean value
of 618 mllmin. It decreased significantly during hANP infusion
with a time—lag of 30 minutes from a mean control value of 625
20 mllmin to 560 20 ml!min (Table 1). As a consequence,
the filtration fraction rose from a mean control value of 19.6% to
23.1% during the hANP infusion (Table 1). When renal blood
flow was calculated from the ERPF by correcting for the
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Fig. 1. Effect of a 2 hour infusion ofhANP2j.g/min (hatched columns) and its vehicle
(blank columns) on urine flow rate (left upper
panel), fractional excretion of water (right
upper panel), osmolar clearance (left lower
panel) and free water clearance (right lower
panel). The significance of differences versus
baseline is presented by asterisks, and versus
vehicle by P < 0.05 (•), P < 0.01 (•S) and
P < 0.001 (S••).
Table 1. Effect of a infusion of 2 g/min hANP or its vehicle on renal
hemodynamic
C T R
GFR Ve 122 4.6 117 2.9 118 2.2
ml/min hANP 120 3.7 125 3.0 116 2.7
ERPF Ve 647 17 608 15 614 10
mllmin hANP 625 20 560a 20 581 18
FF Ve 18.9 0.6 19.3 3.4 19.3 0.4
% hANP 19.6 1.0 23•1E 0.9 20.5 0.8
a P < 0.05 vs. Cb p < 0.01 vs. C
P < 0.001 vs. C
d P < 0.05 vs. Ve
P < 0.01 vs. Ve
fp <0.001 vs. Ve
Abbreviations are: GFR, glomerular filtration rate; ERPF, effective
renal plasma flow; FF, filtration fraction; Ye, vehicle; C, control
periods, T, infusion periods; R, recovery periods.
observed increase in hematocrit during hANP infusion, no
difference was seen during and between the two phases of the
study.
Fluid and solute excretion
The amount of fluid administered was calculated to ensure a
urine flow rate of approximately 14 mI/mm, such as, a marked
water diuresis. During the vehicle infusion the mean urine flow
rate was 13.5 0.5 ml/min. During hANP it increased signifi-
cantly from a mean control value of 14.4 0.7 ml/min to a mean
high of 21.2 1.1 ml/min at one hour. It remained elevated for
the duration of the infusion and was followed by a relative
antidiuresis during the recovery period (Fig. 1, left upper
panel). The pattern of fractional water excretion (FEH2O), in the
absence of a change in GFR, was similar to that seen for urinary
flow rate (Fig. 1, right upper panel). Plasma concentrations of
sodium and chloride remained unchanged during the two phases
of the study while plasma lithium concentration decreased
slightly and similarly from a mean control value of 0.13
mmol!liter to 0.09 mmol/liter at the end of both phases.
Mean sodium excretion during the 24 hours prior to the
experiment, a measure of the daily sodium intake during the five
preceding days, was 232 28 and 257 24 mmol for vehicle
and hANP phases, corresponding to a calculated intake of 13.5
and 14.9 g NaC1 per day, respectively. The amount of sodium
administered as a result of the infusion of fluid containing inulin,
PAH and lithium was approximately 250 mol/min, to which
the infusion of the glucose/saline solution added 250 prnol/min.
The total amount of blood withdrawn during each study phase
was approximately 100 ml.
During the control periods, mean sodium excretion was 336
and 369 .tmollmin for vehicle and hANP phases, respectively.
A gradual increase in sodium excretion was observed during the
vehicle phase, reaching 567 mol/min during the recovery
period. Natriuresis was 2.5 times the respective vehicle value
(2.9 times the control value) during the hANP infusion (Table
2). Similarly, fractional excretion of sodium increased slightly
during the vehicle phase from a mean control value of 2% to a
high of 3.7% at the end of the experiment. During the hANP
phase, fractional excretion of sodium increased from a mean
2.2% (control) to a high of 7.4% at two hours after starting the
hANP infusion to drop below the vehicle value at the end of the
experiment (Fig. 2, upper panel).
Chloride excretion followed a pattern similar to that of
sodium (Table 2). When the sum of urinary sodium and potas-
sium excretion was plotted against chloride excretion, a linear
hANP or vehicle infusion
I]]]]
—0.5 0 0.5 1 1.5 2 2.5 3 3.5 4
hANP or vehicle infusion
Ii
—0.5 0 0.5 1 1.5 2 2.5 3 3.5 4
hANP or vehicle infusion
14
—0.5 0 0.5 1 1.5 2 2.5 3 3.5 4
Time, hours
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Table 2. Effect of a 2 hour infusion of 2 tg/min hA
on electrolyte excretion
NP or its vehicle
C T R
UNa V Ve 336 41 421 4 567 52
p.mol/min
U1 ' V
hANP
Ve
369 37 1055 79
247 40 358 47
648
501 53b
jimol/min
UK' V
hANP
Ye
307 37 989 80cf
36.6 4.0 60.6 50b
636 49C
72.8 3.2c
i.unollmin hANP 55.6 7.l' 98.9 S.8' 77.6 4.6k'
UL V Ve 7.23 0.26 5.83 O.19c 5.05 0.16c
p.mol/min hANP 7.08 0.32 7.71 O.33 5.35 O.19c
V Ye 6.85 0.61 5.29 0.32a 4,67 037b
iimol/min hANP 6.90 0.34 12.02 0.59 5.23 053q
UMg ' V
jsmol/min
Ye
hANP
5.31 0.47 3.55 0.27c
4.76 0.27 7.08 0•34cf
2.69 0.22c
2.99 0.28c
UphOa V Ye 15.92 2.30 18.19 1.33 26.86 1.47c
pinol/min hANP 17.19 2.31 25.26 1,76b,c 19.84 1.47c
V Ye 3.08 0.28 2.71 0.10 2.72 0.14
jimol/min
UPH
hANP
Ye
hANP
2.92 0.14 3.69 017b,f
6.08 0.08 6.31 004b
6.15 0.02 6.57 003c.f
2.76 0.14
6.39 0.03c
6.19 0.06
Uosm Ye 78.7 7.31 107.3 7.9la 127.1 715b
mOsm/kg hANP 98.2 8.43 144.4 8.50" 198.4 ll.5l
a < 0.05 C
b P < 0.01 vs. C
P < 0.001 vs. C
d P < 0.05 vs. Ye
e p < 0.01 vs. Ye
'p < 0.001 vs. Ye
Abbreviations are: Ve, Vehicle; C, control periods; T, infusion
periods; R, recovery periods; urinary excretion of sodium (UNa .
chloride (U1 ' Y), potassium (UK 'Y), lithium (UL, . V), calcium
(Ua 'Y), magnesium (UMg ' V), phosphate (Upho, ' V), and urate(Uur ' Y).
relationship was observed with a slope not different from the
line of identity in both phases (vehicle: y = 0.98x — 119, r =
0.99, N = 80, P < 0.001; hANP: y = 0.94x — 72, r = 0.99, N =
80, P < 0.001).
Lithium excretion decreased slightly during the vehicle phase
from a mean control value of 7.2 0.3 .tmolJmin to a mean
value of 5.8 0.2 prnol/min during the vehicle infusion and 5.1
0.2 mol/min during the recovery period. Starting from a
mean control excretion value of 7.1 0.3 imol/min lithium
excretion increased slightly during hANP to a mean value of 7.7
0.3 prnollmin and returned toward vehicle during the recov-
ery period (Table 2). Fractional excretion of lithium (Fig. 2,
middle panel) remained constant around 47% during the vehicle
phase. It increased to approximately 57% (P < 0.01) during
hANP, and returned toward vehicle at the end of the recovery
period. There was a highly significant proportionality (P <
0.001) between lithium clearance and urine flow.
During the vehicle phase, urinary calcium and magnesium
excretion decreased from mean control values of 6.9 0.6 and
5.3 0.5 .tmolImin to a new mean steady excretory level of 4.6
0.3 and 2.7 0.2 smolJmin, respectively. Duirng the hANP
phase, calcium and magnesium excretion increased from mean
control values of 6,9 0.3 and 4.8 0.3 tmolImin to 12.0 0.6
and 7.1 0.3 jsmol/min, respectively (Table 2).
Mean urate excretion remained stable during the vehicle
phase, but increased progressively with hANP infusion from 2.9
to 3.7 molImin (Table 2). When the difference in urine flow
Fig. 2. Influence of a 2 hour infusion of hANP 2 gImin or its vehicle
on fractional exretion rate of sodium (upper panel), lithium (middle
panel) and on the calculated distal tubular rejection fraction of sodium
(lower panel). Symbols as for Figure 1.
rate was plotted against the change in urate excretion between
the vehicle and hANP infusions, a linear relationship was
obtained (y = 112 x + 250 r 0.86; P <0.001). Mean phosphate
excretion increased significantly over control values during
both phases of the study, although significantly more during
hANP (Table 2). Mean urinary excretion of potassium in-
creased during both phases. However the rise seen during
hANP infusion was significantly greater than that seen during
the vehicle infusion (P < 0.001) (Table 2). Similarly, fractional
excretion of potassium increased with time during both phases,
although significantly more during hANP infusion.
The calculated proximal fractional reabsorption of sodium
remained stable at a mean value of 53% during the vehicle
phase. During hANP-infusion, a significant decrease in the
proximal fractional reabsorption of sodium could be seen from
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C T R
PRR Ye 64.3 4.9 61.3 2.5 64.5 2.9
mi/mm hANP 65.4 3.9 54.4 3.1 57.4 2.3
FPRNa Ye 51.9 2.4 52.3 1.7 54.1 1.8
% hANP 53.9 2.0 43.2 21cf 49.2 1.4"
ADRNa Ye 7.8 0.3 7.5 0.3 7.0 0.3
mmollmin hANP 7.3 0.3 9.0 0.4cr 7.7 0.3
FDRNa Ye 96.0 0.4 94.7 0.4 92.7 0.6c
% hANP 95.3 0.3 89.6 o6cf 92.3 0.4c
DDc, Ye 11.7 0.8 10.2 0.5 10.2 0.6
% hANP 10.6 0.6 15.4 O.8 8.4 0.6
AYP Ve 0.25 0.08 0.21 0.06 0.28 0.08
pg/mi hANP 0.39 0.1 0.39 0.08 0.30 0.05
a < 0.05 vs. C
b < 0.01 vs. C
P < 0.001 vs. C
" P < 0.05 vs. Ye
P < 0.01 vs. Ye
P < 0.001 vs. Ye
Abbreviations are: Ye, Yehicle; C, control periods; T, infusion
periods; R, recovery periods; PRR, absolute rate of proximal reabsorp-
tion of isotonic fluid; FPRNa, proximal fractional reabsorption of
sodium; ADRNa, Absolute distal reabsorption of sodium; FDRNa,
fractional distal reabsorption of sodium; DDc,, Distal delivery of
chloride; AYP, arginine vasopres sin.
Mean SEM
one hour to 2.5 hours (P < 0.01; Table 3). A slight trend toward
a decrease in the calculated absolute rate of proximal reabsorp-
tion of isotonic fluid was noticeable with hANP, without
reaching statistical significance, however (Table 3). The abso-
lute, post-proximal sodium reabsorption significantly increased
from one to 2.5 hour of the hANP phase (Table 3), while the
distal tubular rejection fraction was markedly increased during
the entire infusion of hANP and the first half—hour of the
recovery period (Fig. 2, lower panel). Similarly, the distal
delivery of chloride was significantly increased by hANP, while
simultaneously its distal fractional absorption was markedly
depressed (Table 3).
The sodium—calcium as well as the sodium—magnesium ratios
in the urine increased linearly over time in both vehicle and
hANP phases, although in the latter the increase was somewhat
less during the last hour of the infusion as manifested by a
tendency to a flattening of the curve (Fig. 3, middle panel). The
urinary sodium/potassium ratio decreased slightly during vehi-
cle infusion and increased during hANP (Fig. 3, lower panel),
returning to control values in both phases afterward.
Mean urine osmolality was expectedly low to start with
(Table 2), increased slightly during the vehicle phase but
substantially during hANP, although remaining well below
plasma osmolality. The latter remained unaltered at 287
mOsmollkg H20 during both phases. The osmolar clearance
tended to increase somewhat during the vehicle phase with
values being significantly higher than control value at the end of
the experiment (P < 0.01 vs. control). During hANP the
osmolar clearance increased markedly, following a pattern
similar to that of sodium and chloride excretion (Fig. 1, lower
left hand panel). Free water clearance decreased slightly during
the vehicle phase from a mean control value of 11.6 0.8
hANP or vehicle infusion
E 240
'a
160
'a.—
80
0
(.1) 0
—0.6 0 1 2 3 4
ml/min to reach a plateau around 7.3 0.2 mllmin from 1.5
hours to the end of the recovery period. During the hANP
phase, free water clearance remained at values slightly higher
than control during the first two infusion periods, returned to
values similar to vehicle during the last two before dropping
below them during the first two recovery periods (Fig 1, right
hand panel).
Urinary pH increased gradually during both phases of the
study, although statistically more during hANP. After stopping
the latter, urinary pH dropped significantly below vehicle
values (Table 2).
Hematocrit decreased slightly during the vehicle phase from
a mean control 42.2% to an end recovery value of 40.8%. It rose
rapidly and markedly during hANP from a control 42.2% to
46.8% at two hours (P < 0.001). It returned slowly toward
vehicle values, being still significantly higher at the end of the
recovery period (P <0.05) (Fig. 4). Total protein concentration
in the plasma increased slightly from 63.1 (control) to 66.6
Table 3. Calculated values for absolute and fractional reabsorption of
sodium in proximal and distal tubular segments before, during and
after a 2 h infusion of 2 rg/min hANP or its vehicle 160
0
120
E
. 80
E
40
hANP or vehicle infusion
12
0
10
E
a)
a)
cc 80
a-
E 6
Cd,
0
—0.5 0 1 2 3 4
Time, hours
Fig. 3. Time course of the ratio of the urinary excretion of
sodium/calcium (A), sodium/magnesium (B) and sodium/potassium (C)
before, during and after a 2 hour infusion of 2 pg/min hANP (•) or its
vehicle (0).
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35 U
—1 0 1 2 3 4
Time, hours
Fig. 4. Effectofa 2 hour infusion of hANP 2 ixg/min (•) or its vehicle(0) on the hematocrit of salt loaded volunteers undergoing maximal
water diuresis. Symbols are: (x) P < 0.05, (xx) P < 0.01, (xxx) P <
0.001 versus control; ( ) P < 0.05, (.)P < 0.01, (• ) P < 0.001
versus vehicle.
g/liter at two hours of hANP, decreasing thereafter to 60.3
glliter at the end of the recovery period. Mean body weight was
71.3 and 71.6 kg at the beginning and 73.2 and 72.7 kg at the end
of vehicle and hANP phases, respectively.
Mean plasma, immunoreactive arginine—vasopressin levels
were very low during control periods (vehicle: 0.25 0.08;
hANP: 0.39 0.1), at or below the detection limit of the method
(0.25 pg/mI), and remained suppressed during both phases of
the study.
Discussion
The mechanism of ANP-induced increases in renal solute
excretion is not yet clearly defined. Among potential contribut-
ing factors, increases of GFR [1—41, redistribution of blood flow
[251, or a direct effect on sodium reabsorption either in proximal
tubules [26], the loop of Henle [27] or collecting ducts [10,28,291
have been described. As suggested by various authors, the final
natriuretic effect of ANP might result from the contribution of
several concomitant mechanisms.
Hemodynamics
Marked natriuresis occurred in our study despite near con-
stancy of GFR. This finding suggests that in humans, GFR is
not a prime determinant of ANP induced natriuresis. This
conclusion is consonant with previous experimental evidence
indicating that acute volume expansion may elicit a marked
natriuretic response even in the face of a decreased GFR [30],
and that an acute increase in GFR per se has little effect on
sodium excretion unless extravascular volume is expanded [31].
In both situations, the main determinant of natriuresis is not the
GFR level but the state of fluid and sodium balance. Thus,
although sodium excretion can vary with the filtered load, the
physiological control of sodium excretion involves mechanisms
that operate mainly at the tubular level. Our observations are in
agreement with results reported so far in human beings, where
GFR either remained unchanged, or increased only modestly
and transiently at higher doses of ANP [14,32,33]. Only in one
study [34] a huge but very transient increase of GFR (appreci-
ated by endogenous creatinine clearance) was observed at the
onset of the ANP-induced diuresis, and this might have resulted
not from a direct effect but rather from a washout of creatinine
in the dead space of the urinary tract [35].
Marked increases in GFR after ANP have been reported in
experimental studies pointing to the existence of important
species differences. It has been known long ago that GFR in
dogs is rather labile and can double very rapidly [36,37], while
in rats volume load may increase GFR by as much as 35% [38].
In contrast, GFR in man is less affected by various physiologic
influences such as exercise, emotional stress, meals and hydra-
tion [39].
The dose of ANP administered is another important element
to be considered in appreciating these different results between
human and animal studies. It has been shown in rats that at low
doses no change in GFR was noticeable while with high doses
GFR was increased [13]. Experiments done in dogs and rats
reporting increases in GFR following synthetic ANP injection
and/or infusion [2,3,131 used high doses compared to those used
in humans.
ANP has ben reported to increase, decrease or not to change
renal plasma flow in animals [5]. In humans, ANP infusion has
been shown to induce a decrease of ERPF [14,32,40], a finding
which is similar to the present results. PAH extraction was not
measured in these studies, but the accuracy of PAH clearance
as a measure of renal plasma flow during ANP infusion has been
validated in animals by an electromagnetic flowmeter [2]. Part
of this decrease in renal plasma flow could be explained by the
increased hematocrit. In fact when the renal blood flow was
calculated by correcting for the measured hematocrit, it re-
mained almost unchanged. Increased hematocrit values have
been reported to reduce renal blood flow and to increase renal
vascular resistance and filtration fraction [41,42].
The early increase in the filtration fraction observed after
starting the infusion of hANP has been a consistent finding both
in animal and human studies. This suggests that ANP facilitates
glomerular ultrafiltration. The filtration fraction determines
peritubular capifiary oncotic pressure and partially hydrostatic
pressure and flow rate. The rise in the filtration fraction, by
increasing protein concentration and hence oncotic pressure in
the efferent arteriole, is expected to enhance proximal solute
reabsorption [43]. On the contrary, alterations of flow rate and
peritubular capillary hemodynamics, and expansion of the
interstitium, as suggested by the increase in hematocrit, which
governs fluid uptake from the renal interstitium and modulates
proximal fluid reabsorption, may have increased peritubular
hydrostatic pressure. The latter is expected to decrease proxi-
mal sodium reabsorption [44,45].
Tubular effects
In an attempt to delineate the tubular site(s) of action of ANP
on fluid and electrolyte reabsorption, we used established
clearance techniques [46,47] as well as lithium clearance, which
has been shown to be a good indicator of the rate of proximal
tubular fluid delivered into the thin descending loop of Henle at
normal or high Na supply [15,16,47]. It is therefore possible
from the clearances of lithium and sodium to calculate the
absolute and the fractional reabsorption of sodium in the
proximal as well as in the distal (or post-proximal) segments.
hANP or vehicle infusion
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This latter segment, as defined by the use of lithium clearance,
includes the thin descending and the thin and thick ascending
limb of Henle's loop, the distal convoluted tubule, the collect-
ing tubule and the collecting ducts.
The fractional excretion of lithium observed in our study is
greater than that reported in normal subjects (20 to 30%). This
may be explained first by the sodium loading of our volunteers,
which is known to enhance lithium excretion, second by the
volume expansion under which 50 to 60% of the glomerular
filtrate may escape reabsorption in the proximal tubule, and
third by the 5% glucose infusion and the small amount of
mannitol used as solvent, which may have further increased the
fraction of glomerular filtrate escaping reabsorption in the
proximal tubule [48].
Our study shows that the natriuresis induced by hANP was
accompanied by a 28% increase in lithium clearance, indicating
an increased fluid outflow from the proximal tubule. Confirming
this finding obtained from lithium clearance, the calculated
delivery of chloride beyond the proximal nephron to the distal
tubule was also increased. Furthermore, since in the AVP free
state, fractional water excretion can be used to identify a
proximal tubular action [23], the observed increase in fractional
water excretion suggests a significant inhibitory effect of ANP
on proximal fluid reabsorption. The hANP-induced decline in
proximal reabsorption may be related to alterations of physical
factors controlling in part proximal fluid reabsorption [44,45], as
discussed above, but could also be due to a direct inhibitory
effect of hANP on sodium reabsorption. Indeed ANP has been
shown to decrease sodium transport in membrane vesicles of
rat proximal tubules [49], but on the other hand was reported to
be without effect on proximal rabbit tubules in vitro [501.
Free water clearance has been taken as an index of sodium
chloride reabsorption by the cortical thick ascending limb of the
loop of Henle during water diuresis [46,511. Free water forma-
tion was not impaired in our experiment, providing therefore,
no evidence for a decrease in solute transport in the loop of
Henle and no evidence either for a diminished, medullary
interstitial tonicity during hANP infusion. We cannot totally
exclude, however, that the increased delivery from the proxi-
mal tubule might have concealed a small inhibitory effect on the
ascending limb of Henle's loop. It should also be recalled that
free water clearance is not a precise quantitative measure of
ascending limb transport. It is noteworthy, though, that ANP
did not modify electrolyte transport in isolated, thick ascending
limbs studied in vitro [52]. The decrease in free water clearance
at the end of the hANP infusion and after stopping hANP is
difficult to explain in the absence of any elevation in AVP
levels. Renal hemodynamic changes, as a result of hANP-
induced reduction of the effective intravascular volume, may
represent a possible explanation.
Enhanced distal sodium reabsorption has been shown to
occur in a number of conditions where delivery from the
proximal tubules was increased [53—55]. When calculating the
absolute reabsorption of sodium in the distal segments of the
nephron from the clearances of sodium and lithium, we ob-
served indeed an expected, albeit small, increase in the rate of
sodium reabsorption. By contrast, the calculated, fractional
distal reabsorption of sodium was markedly depressed. This
indicates that the distal segment was unable to compensate for
the increased load from the proximal tubules. This reabsorptive
defect is qualitatively similar to that reported to occur during
extracellular fluid volume—expansion [53,56]. Its expression,
though, was markedly enhanced by hANP infusion, since the
fraction of sodium distally rejected increased by nearly 100%
when compared to controls. Since sodium reabsorption in the
distal nephron remains unsaturated even at high delivery rate
[53], our results provide a strong argument for an important
distal contribution to hANP-induced natriuresis.
The excretory pattern of other electrolytes may further
delineate the renal site of action of hANP. A slight increase in
phosphate excretion was observed during both phases of the
study. Phosphaturia was significantly more marked during
hANP, confirming therefore the proximal effect shown with
lithium clearance. Sixty to 70% of ultrafiltered calcium is
reabsorbed by the proximal tubule, 20 to 30% by the loop of
Henle and the distal tubule, Diuretics acting proximally, such as
acetazolamide, inhibit proximal tubular reabsorption of sodium
and calcium, increasing their delivery to the distal nephron. As
a result, sodium excretion increases but calcium excretion does
not. There seems to be a preferential reabsorption of the
delivered load of calcium in the distal nephron [57]. Therefore,
the calciuria observed in our study cannot be explained by a
decreased proximal reabsorption alone and therefore suggests a
post-proximal action of hANP on calcium excretion. Loop—ac-
tive natriuretic agents inhibit calcium transport and produce a
marked calciuria that may be proportionately greater than the
corresponding natriuresis. We observed no lack of proportion-
ality between sodium and calcium excretion, the excretion ratio
remaining similar during both phases. This finding, together
with the lack of inhibition of free water formation, suggests no
effect of hANP on the loop of Henle, and points therefore to an
effect on the distal tubule. Thiazides diuretics acutely increase
the urinary sodium to calcium ratio. Since this ratio did not
change, hANP effects are different from those of thiazides.
The slight but statistically significant increase in urate excre-
tion is probably related to increases in urine flow which have
been shown to influence urate clearance in humans [58]. The
close linear relationship obtained between the change in urine
flow rate and urate excretion strongly suggests such an expla-
nation, although we cannot absolutely exclude a more direct
effect on reabsorption or secretion.
The sodium load and the progressive rise in distal tubular
flow rate are probably responsible for the increased potassium
losses observed during both hANP and vehicle phases [59]. The
increase in the sodium/potassium ratio during hANP contrasts,
however, with the decrease observed during vehicle. This
alteration in NaJK ratio indicates that hANP-induced natriure-
sis is accompanied by relatively less K excretion, suggesting
once again a distal inhibition of sodium transport.
Distal hydrogen secretion is also dependent on sodium reab-
sorption. A decreased distal sodium reabsorption may therefore
explain the increased urinary pH during hANP and, conversely,
its drop after the effect of hANP has vanished. Although of
marginal significance, this pH rise again points to a distal effect
of hANP.
It has been observed in humans that an increase of hematocrit
is accompanied by a rise of the filtration fraction and a reduc-
tion of the filtration rate [60—62]. The changes of hematocrit
observed with continuous infusion of ANP may therefore
account for part of the alterations of renal hemodynamics,
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including renal plasma flow or renal blood flow, renal vascular
resistance and filtration fraction. Such changes of hematocrit
are probably absent or less marked following a bolus injection
of ANP, and this may contribute to the differences which have
been reported in the effects of ANP on renal hemodynamics.
The increase in hematocrit observed during hANP infusion
started too early and was of a magnitude which cannot be
explained solely by urinary losses of fluid and electrolytes. By
analogy to the increased filtration fraction observed in the
kidney, one may speculate that hANP may increase net filtra-
tion in other capillary beds either by increasing capillary
permeability or by altering Starling forces. Fluid shift between
intra- and extra-vascular compartments could represent a char-
acteristic feature of hANP and explain some of its effects. It
was recently shown that similar rise in hematocrit occurred in
nephrectomized rats infused with ANP, and this was accompa-
nied by an approximately 10% fall in circulating plasma volume
[63].
Plasma levels of ANP have not been measured in this study.
They have, however, been estimated in salt—loaded volunteers
studied under similar conditions at ANP infusion rates ranging
from 0.5 to 5 /.Lg/min during four hours [14,40,641. The plasma
levels were linearly related to the dose. One may therefore
extrapolate and conclude that, under the infusion rate used in
this study, such as 2 zg/min, plasma levels of ANP should have
been around 900 to 1000 pg/mi, that is, plasma concentrations
corresponding to the upper range of those measured under
pathophysiological conditions such as congestive heart failure,
and various congenital heart and pulmonary diseases [65, Goy
unpublished].
Conclusion
In conclusion, the marked natriuresis induced by a two-hour
infusion of hANP in salt—loaded and volume—expanded normal
volunteers resulted almost entirely from tubular rather than
glomerular effects of the peptide. Our results suggest that water
and solute reabsorption is reduced by ANP in both the proximal
(possibly through alterations of Starling forces) and the distal
segments of the nephron.
The association of two mechanisms and sites of action may
explain the high diuretic—natriuretic efficacy of ANP, since the
distal inhibitory effect prevents the blunting of the natriuresis
induced proximally. The similarity between hANP and isotonic
volume expansion with respect to the characteristic changes of
sodium net reabsorption along the nephron, as well as the
relationship existing between sodium loading and the level of
the natriuretic effect of hANP suggest that ANP plays a major
role in the natriuresis induced by extracellular fluid volume—
expansion.
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Appendix: abbreviations and formulas
Inulin clearance
Glomerular filtration rate = C1
Para-aminohippurate (PAH) clearance
Effective renal plasma flow = CPAH
Renal blood flow — ERPF/(1-hematocrit)
Fractional excretion (clearance of x expressed as
% of C1, or clearance of x expressed as milliter
per 100 ml of inulin clearance
Free water clearance VCosm
Osmolar clearance Uosm X V/Posm
Distal delivery of chloride (CH2O + Cc1)/GFR X
100
DFAc, : Distal fractional chloride absorption CH2O/(CH2o
+ Cc1)
FDRNa : Fractional distal (=post-proximal) sodium reab-
sorption ((FELt - FENa)/FELi) X 100
DTRFNa : Distal tubular rejection fraction of sodium 100 —
FDRNa (%)
FPRNa : Proximal fractional reabsorption of sodium 1-
FEL
PRR : Absolute rate of proximal reabsorption of
isotonic fluid CIn-CLI
ADRNa : Absolute distal sodium reabsorption
(CLICNa) X PNa
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